Shandong Wohua Pharmaceutical (002107) Stock Overview
Manufactures and sells pharmaceutical products in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
002107 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
Read full narrativeShandong Wohua Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥7.38 |
| 52 Week High | CN¥8.47 |
| 52 Week Low | CN¥5.10 |
| Beta | 0.41 |
| 1 Month Change | -1.99% |
| 3 Month Change | 0.96% |
| 1 Year Change | 41.65% |
| 3 Year Change | 17.14% |
| 5 Year Change | -3.78% |
| Change since IPO | 146.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| 002107 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 1.0% | -0.2% | 3.2% |
| 1Y | 41.7% | 6.6% | 36.5% |
Return vs Industry: 002107 exceeded the CN Pharmaceuticals industry which returned 6.6% over the past year.
Return vs Market: 002107 exceeded the CN Market which returned 36.5% over the past year.
Price Volatility
| 002107 volatility | |
|---|---|
| 002107 Average Weekly Movement | 7.0% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in CN Market | 9.9% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 002107 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002107's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 1,018 | Shengting Li | www.wohua.cn |
Shandong Wohua Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in China. The company produces and sells tablets, granules, capsules, oral liquid, and pills; medicinal herb cultivation; and provides pharmaceutical technology consulting services. It also offers products including drugs for cardiovascular, cerebrovascular, and nervous system diseases, such as Wohua Xinkeshu tablets, Hedan tablets and capsules, Naoxueshu and Shenzhiling oral liquid, and Tongluo Huatan capsules; and drugs for musculoskeletal disorders, including Gusukang capsules/granules and Yidu Hanbi liquid; Yidu cold-rheumatism medicinal wine ingredients; brain blood circulation oral solution; Amber stone granules for urinary system diseases; Children's antipyretic granules for pediatric medication; Anti-itching granules for skin diseases; and Bile grass capsule for digestive and gynecological diseases, as well as Silkworm Nourishing Blood and Benefiting Kidney Granules for gynecological medication.
Shandong Wohua Pharmaceutical Co., Ltd. Fundamentals Summary
| 002107 fundamental statistics | |
|---|---|
| Market cap | CN¥4.26b |
| Earnings (TTM) | CN¥109.50m |
| Revenue (TTM) | CN¥818.16m |
Is 002107 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002107 income statement (TTM) | |
|---|---|
| Revenue | CN¥818.16m |
| Cost of Revenue | CN¥192.54m |
| Gross Profit | CN¥625.63m |
| Other Expenses | CN¥516.12m |
| Earnings | CN¥109.50m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.19 |
| Gross Margin | 76.47% |
| Net Profit Margin | 13.38% |
| Debt/Equity Ratio | 0% |
How did 002107 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/11 20:12 |
| End of Day Share Price | 2026/05/11 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shandong Wohua Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.